|
|
Copyright
© 2008
Connective Tissue Oncology Society
All Rights Reserved
|
|
CTOS
12th Annual Meeting
November 2–4, 2006
Hotel
Monaco and Grand Canal
Venice, Italy
Schedule: Wednesday
| Thursday | Friday |
Saturday
Wednesday, November 1 |
| 5:00
PM– 7:00 PM
Hotel Lobby |
Registration and
Poster Set-Up |
| Thursday, November 2 |
| 7:00
AM–5:00 PM
Hotel Lobby |
Registration
and Poster Set-Up |
| 7:00 AM–8:00
AM
Second Floor |
Continental
Breakfast |
| 8:00 AM–12:00
PM
Salon del Ridotto |
SARC
Meeting
|
| 8:00 AM–12:00
PM
TBD |
CTOS
Nurse and Allied Health Professionals Conference
|
| 1:00 PM–1:15
PM
Salon del Ridotto |
CTOS
12th Annual Meeting: An Introduction |
| 1:15 PM–2:25
PM
Salon del Ridotto |
Session
1 — Molecular Genetics
of Sarcomas and Treatment Implications
Moderator: Junya Toguchida, MD, PhD
|
| |
(713)
IDENTIFICATION OF NOVEL ONCOGENES IN LIPOSARCOMA USING
TRANSCRIPTIONAL PROFILING AND ARRAY-BASED COMPARATIVE
GENOMIC HYBRIDISATION
D M Thomas1; T Morgan1; P F Choong1;
I Dickinson3; J Slavin4; S Schlicht4;
G Powell4; P Crowe2
1Peter MacCallum Cancer Centre, Melbourne,
Victoria, Australia; 2Prince of Wales Hospital,
Sydney, NSW, Australia; 3Wesley Hospital,
Brisbane, Queensland, Australia; 4St Vincents
Hospital, Melbourne, Victoria, Australia |
| |
(617)
DUAL ROLE OF CD99 AS ONCOSUPPRESSOR OR ONCOGENE IN OSTEOSARCOMA
AND EWING’S SARCOMA: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS.
* K Scotlandi1; M Manara1; A
Rocchi1; M Zuntini1; F Nardi1;
L Cantiani1; M Sciandra1; G Nicoletti1;
P Lollini2; P Picci1
1Istituti Ortopedici Rizzoli, Bologna,
, Italy; 2Universita di Bologna, Bologna,
, Italy |
| |
(556)
RAD51 OVEREXPRESSION CONTRIBUTES TO CHEMORESISTANCE
IN HUMAN SOFT TISSUE SARCOMA (STS); A ROLE FOR P53/AP-2
TRANSCRIPTIONAL REGULATION
J Hannay; J Liu; S Bolshakov; D Yu; A Lazar; * R
Pollock; * D Lev
MD Anderson Cancer Center, Houston, Texas, United
States |
| |
(711)
CXCR4 RECEPTOR IS ASSOCIATED WITH HEMATOGENOUS METASTASES
IN LEYOMIOSARCOMA (LMS), PLEOMORPHIC SARCOMA (PMS) AND
LIPOSARCOMA (LPS).
S Aliberti1; G Grignani1;
A Pisacane1; G Cavalloni1; M Motta2;
Y Pignochino1; I Sarotto1; P Allione1;
B Torchio2; M Risio1; M Aglietta1
1Institute for Cancer Research and Treatment,
Candiolo, Torino, Italy; 2ASO Mauriziano,
Torino, , Italy |
| 2:25 PM–3:20
PM
Salon del Ridotto |
Session
2 — Pathological
and Molecular Diagnosis of Sarcomas
Moderator:
Piero Picci, MD |
| |
(559)
NOVEL EWING SARCOMA TRANSLOCATION IDENTIFIED IN CASE
LACKING EWS GENE REARRANGEMENT
* M J O'Sullivan2; T L Ng2;
T Nielsen1; M Hayes2; P Sorensen2;
D Horsman2
1The University of British Columbia,
Vancouver, BC, Canada; 2BC Cancer Agency
and BC Cancer Research Centre, Vancouver, BC, Canada;
3BC Childrens Hospital, Vancouver, BC, Canada
|
| |
(718)
CORRELATION BETWEEN HISTOLOGY AND KIT/PDGFRA GENE STATUS
IN IMATINIB TREATED GASTROINTESTINAL STROMAL TUMORS
(GIST)
F Miselli; P Casieri; T Negri; M Orsenigo; M S Lagonigro;
* A Gronchi; M Fiore; S Stacchiotti; R Bertulli; P G
Casali; A Carbone; M A Perotti; E Tamborini; S Pilotti
Istituto Nazionale per lo Studio e la Cura dei Tumori,
Milano, , Italy |
| |
(590)
CYCLOOXYGENASE-2 OVEREXPRESSION ASSOCIATED WITH A POOR
PROGNOSIS IN CHONDROSARCOMAS
M Endo1; T Matsumura2; U Yamaguchi1;
F Nakatani1; A Kawai1; H Chuman1;
Y Beppu1; T Hasegawa2
1National Cancer Center Hospital, Tokyo,
, Japan; 2Sapporo Medical University School
of Medicine, Sapporo, , Japan |
| 3:20 PM–3:35
PM
Second Floor |
Coffee
Break |
| 3:35 PM–4:30
PM
Salon del Ridotto |
Session
3 — Pediatric Sarcomas
Moderator: Paul Meyers, MD |
| |
(524)
MICROARRAY ANALYSIS OF EWS/FLI IN EWING'S
SARCOMA REVEALS A CRITICAL ROLE FOR NKX2.2 IN ONCOGENESIS
Leah A. Owen1, Richard Smith1, Deborah
J. Trem1, Jenny S. Wong4, Jennifer
S. Whangbo4, Todd R. Golub5, Stephen
L. Lessnick1
1Huntsman Cancer Institute, Salt
Lake City, UT, United States; 2Primary
Childrens Medical Center, Salt Lake City, UT, United
States; 3University of Utah, Salt Lake
City, UT, United States; 4Dana
Farber Cancer Institute, Boston, MA, United
States; 5Broad Institute, Cambridge, MA, United
States |
| |
(666)
NON- METASTATIC OSTEOSARCOMA: RESPONSE BASED AUGMENTATION
OF THERAPY
C L Schwartz; L H Wexler; M Devidas; L A Teot; A
Goorin; H Grier; M Gebhard; L Steinherz; J Sato; J Healey;
S Lipshultz; J Miser; R Womer; * P Meyers; * M Bernstein
Childrens Oncology Group, Arcadia, CA, United States
|
| |
(743)
PEDIATRIC LIMB SALVAGE WITH THE STANMORE NON-INVASIVE
EXPANDABLE PROSTHESIS - THE UNITED STATES EXPERIENCE
E R Henderson; D Cheong; * G D Letson
Moffitt Cancer Center and Research Institute, Tampa,
Florida, United
States |
| |
(610)
A PRECLINICAL EVALUATION OF ZIO-201 (ISOPHOSPHORAMIDE
MUSTARD (IPM)-LYSINE) IN SARCOMA.
E Kolb1; P Gidwani1; R P Gale2;
* R Gorlick1
1Albert Einstein
College of Medicine, Bronx, NY,
United States;
2ZIOPHARM Oncology Inc, New York, NY, United
States |
| 4:30 PM–5:25
PM
Salon del Ridotto |
Session
4 — Animal Models of Sarcomas
Moderator: Mario Capecchi, PhD |
| |
(606)
REGIONS OF THE CANINE GENOME ASSOCIATED WITH OSTEOSARCOMA
IDENTIFIED BY A WHOLE GENOME CASE-CONTROL ASSOCIATION
STUDY.
K E Comstock1; E K Karlsson2;
C Wade2; E T Keller1; E Lander2;
* L H Baker1; K Lindblad-Toh2
1University of Michigan, Ann Arbor, MI,
United States; 2Broad Institute of Harvard
and MIT, Boston, MA, United States |
| |
(522)
VEGF EXPRESSION CORRELATES WITH FAST GROWTH AND EARLY
METASTASIS IN A NOVEL MODEL OF OSTEOSARCOMA
S Yang; H Yu; J Krygier; M P Mott; P H Wooley
Wayne State University, Detroit, MI, United States
|
| |
(566)
P53 MUTATION IS REQUIRED FOR SARCOMA DEVELOPMENT AND
TUMOR MAINTENANCE IN MICE
* D G Kirsch1; A Ventura2; M McLaughlin2;
D Tuveson2; D Dinulescu2; P Santiago2;
J Grimm1; R Weissleder1; T Jacks2
1Massachusetts General Hosptial, Boston,
MA, United States; 2Massachusetts Institute
of Technology, Cambridge, MA, United States |
| 5:25 PM–6:25
PM
Second Floor |
Poster
Viewing of Sessions 1-4
Session
1 — 544,545,549,563,585,614,642,671,672,679,686,689,697,698,700,704,720,733,734,747,748,764
Session 2 — 513,546,565,570,571,581,583,621,627,650,656,657,714
Session 3 — 551,552,553,600,705,710,719,735,739
Session 4 — 620,628 |
| 6:25 PM–6:40
PM
Salon del Ridotto |
Session
5 — Fascinoma in CTOS: A Review
Moderator: Robert. Maki,
MD |
| 6:40 PM–7:15
PM
Second Floor |
Poster
Viewing of Session 5
Session 5 — 508,515,568,584,630,631,640,654,667,677,721,722,736,737,757,759,761 |
| 7:30
PM–8:30 PM
TBD |
Welcome
Reception and Wine Tasting |
| Friday, November
3 |
| 7:00
AM–5:00 PM
Hotel Lobby |
Registration
& Poster Set-Up |
| 7:00 AM–8:00
AM
Second Floor |
Continental Breakfast
|
| 7:00 AM–8:00
AM
Board Room |
Executive Committee
Meeting |
| 8:00 AM–8:55
AM
Salon del Ridotto |
Session
6 — Initial Management and Surgery
Moderators: Silvie Bonvalot, MD, Alessandro
Gronchi, MD |
| |
(530)
SURGEON-LED BIOPSY WITH INTRAOPERATIVE FROZEN SECTION
IS AN ACCURATE AND COST EFFECTIVE METHOD FOR INITIAL
EVALUATION OF MUSCULOSKELETAL SARCOMAS.
R U Ashford1; S W McCarthy1;
R A Scolyer1; S Bonar2; R Z Karim1;
P D Stalley1
1Royal Prince
Alfred Hospital, Sydney,
NSW, Australia;
2Douglass Hanly Moir Pathology, Ryde, NSW,
Australia |
| |
(558)
ISOLATED LIMB PERFUSION: A NOVEL DELIVERY SYSTEM FOR
WILD TYPE P53 AND FIBER-MODIFIED ONCOLYTIC ADENOVIRUSES
TO EXTREMITY SARCOMA
J Hannay; D Yu; J Liu; * R Pollock; * D Lev
MD Anderson Cancer
Center, Houston, Texas, United States |
| |
(637)
AGGRESSIVE TREATMENT FOR LOCAL RECURRENCE OF ABDOMINAL
SARCOMA – IS IT WORTH IT?
I Nachmany; D Dayan; O Merimsky; G Lahat; J Klausner
Tel Aviv
Sourasky Medical
Center, Tel Aviv, , Israel |
| 8:55 AM–10:20
AM
Salon del Ridotto |
Poster
Viewing of Session 6
Session 6 — 542,543,560,562,573,575,587,591,598,602,609,613,629,644,645,647,653,668,678,681,684,685,707,708,723,728,740
|
| 9:00 AM–10:20
AM
Second Floor |
Coffee Break
|
| 10:20 AM–11:15
AM
Salon del Ridotto |
Session
7 — Cytotoxic Chemotherapy
Moderators: Robert Benjamin, MD, Jean Yves
Blay, MD |
| |
(611)
INCIDENCE OF DELAYS IN CHEMOTHERAPY DUE TO METHOTREXATE
TOXICITY IN TREATMENT OF OSTEOSARCOMA
M Perisoglou; * B Seddon; S Daniels; N Mayne; *
J Whelan
University College Hospital, London,
, United Kingdom |
| |
(676)
SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION
THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED
ADULT PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE
SARCOMA: RESULTS FROM A RANDOMIZED PHASE II TRIAL
M Schuler1; D Pink1; T Lindner1;
D Schoeler2; * J Hartmann3; S
Micheel1; * P Reichardt2
1Robert Roessle Klinik Charite Campus
Buch, Berlin, , Germany; 2Charite Campus
Virchow Klinikum, Berlin, , Germany; 3Universitaet
Tuebingen Medizinische Klinik, Tuebingen, , Germany
|
| |
(652)
FACTORS INFLUENCING SARCOMA TREATMENT
W G Ward1; M T Cline1; F J
Dorey2
1Wake Forest University School of Medicine,
Winston Salem, North Carolina, United States; 2USC
Keck School of Medicine, Los Angeles, California, United
States |
| 11:15 AM–12:30
PM
Second Floor |
Poster
Viewing of Session 7
Session 7 — 511,561,564,569,576,589,596,608,612,623,634,639,675,676,693,695,699,702,712,716,725,728,729,732,744
|
| 12:30 PM–2:00
PM
Second Floor |
Lunch
|
| 12:30 PM–2:00
PM
Board Room |
Board of Directors
Meeting |
| 2:00 PM–3:00
PM
Salon del
Ridotto |
Herman Suit Lecture:
Mario Capecchi
Introduction: Junya Toguchida, MD, PhD |
| 3:00 PM–4:00
PM
Salon del Ridotto |
Session
8 — Imaging and Radiotherapy
Moderators: Haesun Choi, MD |
| |
(755)
MULTIPLE TRACER PET ASSESSMENT OF TREATMENT RESPONSE
IN SOFT TISSUE SARCOMA PATIENTS
* E U Conrad, III; * J F Eary; * J E Butrynski;
J M Link; A M Cizik; D M Mankoff; K A Krohn
University of
Washington, Seattle, WA,
United States
|
| |
(577)
MULTI-MODALITY IMAGING OF PREOPERATIVELY IRRADIATED
SARCOMA PATIENTS DOES NOT PREDICT PATHOLOGICAL OUTCOME.
* R Haas1; L Dewit1; * F Van
Coevorden2; H Peterse3; C Loo4;
R Valdés Olmos5
1The Netherlands Cancer Institute Department
of Radiotherapy, Amsterdam, , Netherlands; 2The
Netherlands Cancer Institute Department of Surgery,
Amsterdam, , Netherlands; 3The Netherlands
Cancer Institute Department of Pathology, Amsterdam,
, Netherlands; 4The Netherlands Cancer Institute
Department of Radiology, Amsterdam, , Netherlands; 5The
Netherlands Cancer Institute Department of Nuclear Medicine,
Amsterdam, , Netherlands |
| |
(710)
PET-CT FUSION IMAGING AND SUV ASSESSMENT USING MIMVISTA
(RESISTING RECIST)
* P Anderson
MD Anderson
Cancer Center,
Houston, TX, United States
|
| 4:00 PM–4:45
PM
Second Floor |
Poster
Viewing of Session 8
Session 8 — 529,531,536,586,599,601,604,635,662,663,669,673,674,682,703,731,745,756,762,763 |
| 4:45 PM–5:30
PM
Salon del
Ridotto |
Diagnostic Competition
Daniel
Vanel, MD |
| 5:30 PM–6:30
PM
Salon del Ridotto |
Members Business
Meeting |
| 7:00 PM–11:00
PM
Palace Pisani Moretta |
Reception and Dinner
|
| Saturday, November 4 |
|
7:00 AM–5:00 PM
Hotel Lobby |
Registration &
Poster Set-Up |
|
7:00 AM–8:30 AM
Second Floor |
Continental Breakfast
|
|
8:30 AM–9:30 AM
Salon del Ridotto |
Session 9 — Patient Advocacy Groups
American
College of Surgeons Oncology Group
Canadian
Sarcoma Group
Children’s
Oncology Group
EORTC
STBSG
European
and American Osteosarcoma Study Group
GSF: Groupe
Sarcome Français; GETO: Groupe d’Etudes des
Tumeurs Osseuses
Intergroup
Coalition Against Sarcomas (ICAS)
Italian Sarcoma
Group
Liddy Shriver
Sarcoma Initiative
Life
Raft Group
MHE Research
Foundation
Sarcoma
Alliance
Sarcoma
UK
The Sarcoma
Working Group for RTOG 0630
Scandinavian
Sarcoma Group
|
|
9:30 AM–10:30 AM
Salon del Ridotto |
Session 10 — The Presentation of Cooperative
Groups: Prospective for Collaborations; Presentation of
Ongoing Collaborative Projects |
|
10:30 AM–10:45 AM
Second Floor |
Coffee Break |
|
10:45 AM–12:00 PM
Salon del Ridotto |
Nina Axelrad Lecture: Lee
J Helman, MD
Introduction: J unya Toguchida, MD, PhD, Luca
Sangiorgi, MD, PhD |
|
12:00 PM–1:00 PM
Second Floor |
Lunch |
|
1:00 PM–2:15 PM
Salon del Ridotto |
Session
11 — Molecular Biology for the Patients: Define New
Targets? Predict Outcome?
Moderators: Ole Steen Nielsen, MD, Irene Andrulis,
PhD |
| |
(619)
PEDF INHIBITS OSTEOSARCOMA GROWTH AND METASTASIS
E T Ek1; C R Dass1; K G Contreras1;
P F Choong1
1St Vincents Hospital Melbourne, Melbourne,
Victoria, Australia; 2Peter MacCallum Cancer
Centre, Melbourne, Victoria, Australia |
| |
(533)
CLEAR CELL SARCOMA AND OTHER TRANSLOCATION-ASSOCIATED SARCOMAS
ARE HIGHLY SENSITIVE TO HISTONE DEACETYLASE INHIBITOR MS-275
S Liu; M A Knowling; P Clarkson; J M Lubieniecka; H
Cheng; * T O Nielsen
University of British Columbia, Vancouver, BC, Canada |
| |
(626)
ANTI-TUMOR IMMUNITY AGAINST AUTOLOGOUS SYNOVIAL SARCOMA
CELLS ELICITED IN VITRO BY CTLS RECOGNIZING THE TUMOR SPECIFIC
ANTIGENS CREATED BY THE RECIPROCAL TRANSLOCATION OF SYT-SSX
L L Chen1; H Sang2; * Y Alan2;
P P Lin2; C O Oyedeji2; E F Wu2;
* J C Trent2; D M Steinert2; * S Patel2;
* R S Benjamin2; M L Frazier2
1Huntsman Cancer Institute of University
of Utah, Salt Lake City, Utah, United States; 2M
D Anderson Cancer Center of the University of Texas, Houston,
Texas, United States |
| |
(742)
A SOLUBLE WNT RECEPTOR SHOWS ANTI-TUMOR ACTIVITY IN OSTEOSARCOMA
Y Guo2; X Zi1; B Sworder1;
H Pamela1; J Xie1; K Ivan2;
* B H Hoang1
1University of California Irvine, Orange,
CA, United States; 2Children Hospital of Orange
County, Orange, CA, United States |
|
2:15 PM–3:30 PM
Salon del Ridotto |
Session 12 — Surgery,
Cytotoxic and Targeted Therapies on GIST
Moderators: Ian Judson, MD,
George Demetri, MD |
| |
(618)
THE UPDATED OUTCOMES OF METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL
STROMAL TUMOR (GIST) PATIENTS TREATED SURGICALLY AFTER RESPONSE
TO TARGETED THERAPY WITH IMATINIB (IM)
* P Rutkowski1; Z I Nowecki1;
P Nyckowski2; W Dziewirski1; U Grzesiakowska1;
A Nasierowska-Guttmejer1; W Michej1;
Z Zurawski1; M Krawczyk2; * W Ruka1
1Maria Sklodowska Curie Memorial Cancer Center
and Institute of Oncology, Warsaw, , Poland; 2Medical
University, Warsaw, , Poland |
| |
(641)
INITIAL RESULTS OF A MULTICENTER SINGLE ARM PHASE 2 STUDY
OF AMG 706, AN ORAL MULTI-KINASE INHIBITOR, FOR THE TREATMENT
OF ADVANCED IMATINIB-RESISTANT GASTROINTESTINAL STROMAL
TUMORS (GIST)
* R Benjamin1; * P Schöffski2;
* J T Hartmann3; * B N Bui4; * J Duyster5;
* S Schuetze6; * J Blay7; * P Reichardt8;
* L Rosen9; * K Skubitz10; M Eschenberg11;
D Stepan11; * L Baker6
1MD Anderson Cancer Center, Houston, TX,
United States; 2University Hospital Gasthuisberg,
Leuven, , Belgium; 3Tubingen University Medical
Center II, Tübingen, , Germany; 4Fondation Bergonie,
Bordeaux, , France; 5Technical University of
Munich, Munich, , Germany; 6University of Michigan,
Ann Arbor, MI, United States; 7Centre Leon Berard,
Lyon, , France; 8Charite Campus Buch, Berlin,
, Germany; 9Premiere Oncology, Santa Monica,
CA, United States; 10University of Minnesota,
Minneapolis, MN, United States; 11Amgen Inc,
Thousand Oaks, CA, United States |
| |
(643)
COMPARATIVE OUTCOMES IN PATIENTS WITH METASTATIC GIST TREATED
WITH IMATINIB AT MAJOR SARCOMA CENTERS FROM THE INTERGROUP
COALITION AGAINST SARCOMAS (ICAS) STUDY (S0033).
* E C Borden6; C J Rankin1; *
C Fletcher2; * R Benjamin5; * M von
Mehren4; * V Bramwell3; J Crowley1;
* G D Demetri2
1SWOG Biostatistics, Seattle, WA, United
States; 2CALGB, Boston, MA, United States; 3NCIC,
Calgary, Alberta, Canada; 4ECOG, Philadelphia,
PA, United States; 5MD Anderson, Houston, TX,
United States; 6SWOG, Cleveland, OH, United States
|
| |
(661)
PREDICTING TOXICITIES FOR PATIENTS WITH ADVANCED GASTRO-INTESTINAL
STROMAL TUMORS (GIST) TREATED WITH IMATINIB: AN EORTC-ISG-AGITG
STUDY.
* M M Van Glabbeke1; * J Verweij2;
* P G Casali3; J Simes4; A Le Cesne5;
* P Reichardt6; R Issels7; * I R Judson8;
* A T van Oosterom9; * J Blay10
1EORTC Data Center, Brussels, , Belgium;
2Erasmus University Medical Center, Rotterdam,
, Netherlands; 3Istituto Tumori, Milano, , Italy;
4NHMRC Clinical Trials Centre, University of
Sydney, , Australia; 5Institut Gustave Roussy,
Villejuif, , France; 6Charite Campus Buch, Berlin,
, Germany; 7Klinikum Grosshadern, Munich, , Germany;
8Royal Marsden Hospital, London, , United Kingdom;
9University Hospital Gasthuisberg, Leuven, ,
Belgium; 10Center Leon Berard, Lyon, , France
|
|
3:30 PM–4:00 PM
Second Floor |
Coffee Break |
|
3:30 PM–4:30 PM
Salon del Ridotto |
Poster Viewing of Session 11 and
12
Session 11 - 525,526,528,538,539,550,555,557,578,579,593,595,597,616,638,660,664,688,701,709,738,765
Session 12 – 646,648,724,727,730 |
|
4:30 PM–5:50
PM
Salon del Ridotto |
Session 13 — Surgery in Sarcomas
Moderators: R. Lor Randall,
MD, Jay Wunder, MD |
| |
(574)
AGGRESSIVE EXTRA-ABDOMINAL FIBROMATOSIS: CAN AGGRESSIVE
MANAGEMENT BE AVOIDED IN A SUBGROUP OF PATIENTS ?
* S Bonvalot1; H Eldweny1; V Haddad1;
* A Le Cesne1; G Missenard1; P Terrier1;
* O Oberlin1; * J Blay2; C Le Pechoux1
1Institut Gustave Roussy, Villejuif,
, France;
2Centre Leon Berard, Lyon,
, France |
| |
(649)
MYXOID LIPOSARCOMA:PROGNOSTIC FACTORS AND SURVIVAL IN A
SERIES OF PATIENTS TREATED AT A SINGLE INSTITUTION.
M Fiore; F Grosso; S Lo Vullo; C Mussi; * S Stacchiotti;
P Collini; L Lozza; L Mariani; * P G Casali; * A Gronchi
Istituto Nazionale per lo Studio e la Cura dei Tumori,
Milan, , Italy
|
| |
(750)
CLINICAL UTILITY OF A NEW CLASSIFICATION OF SURGICAL MARGINS
* E Y Cheng1; P Zwolak1; C T Le2;
J C Manivel3; K E Dusenbery4; D R
Clohisy1; * K M Skubitz5; R C Thompson1
1University of Minnesota Cancer Center Orthopaedic
Surgery, Minneapolis, Minnesota, United States; 2Univ
MN Department Biostatistics, Minneapolis, Minnesota, United
States; 3Univ MN Pathology, Minneapolis, MN,
United States; 4Univ MN Radiation Oncology, Minneapolis,
MN, United States; 5Univ MN Medical Oncology,
Minneapolis, MN, United States |
| |
(751)
SURGERY VS RADIOTHERAPY IN NONMETASTATIC EWING’S SARCOMA
OF THE EXTREMITIES: EXPERIENCE OF A SINGLE INSTITUTION
* N Fabbri; G Bacci; S Ferrari; A Longhi; D Donati;
M Manfrini; E Barbieri; P Picci; M Mercuri; F Bertoni
Istituto Ortopedico Rizzoli, Bologna, , Italy |
|
5:50 PM–6:50 PM
Second Floor |
Poster
Viewing of Session 13
Session 13 – 509,510,518,519,520,532,534,535,540,541,572,582,588,592,605,607,615,632,659,683,687,706,741,746,749,753,754,760
|
|
6:50 PM–7:30 PM
Salon del Ridotto |
Conclusion and Closure of the
Meeting |
|
|
